YAZ, MD

Doctor, Assoc Ed at Tweets are my own, not medical advice. RT & URL for educational purpose only. Not responsible for URL content.

[C. Michael Gibson MD @CMichaelGibson]

Dr. Maura Marcucci and Dr. @YazDaaboul discuss results from POISE 3 trial for perioperative BP management in non-cardiac surgery. Interview link here: https://t.co/8Ak48WByS1 #cardiology #surgery

[C. Michael Gibson MD @CMichaelGibson]

ADAPT-TAVR trial: in TAVR patients, edoxaban similar to DAPT in incidence of leaflet thrombosis on CT scans, no difference in rate of new cerebral thromboembolism. Download full slides from ADAPT-TAVR here: https://t.co/A2kKGSaPBG #cardiology #tavr

[C. Michael Gibson MD @CMichaelGibson]

GIPS-IV trial: sodium thiosulfate after MI not associated with reduction in infarct size. Download slides from GIPS-IV here https://t.co/Mn6VC7xvbW #cardiology

[YAZ, MD @YazDaaboul]

@CMichaelGibson #icon ❤️

[C. Michael Gibson MD @CMichaelGibson]

Results from Rilonacept Phase 2 trial presented at AHA 2019 show rapid resolution of recurrent pericarditis episodes and improvement in quality of life scores.

Full poster here:
https://t.co/FN0EytanEp

Sponsored by an unrestricted educational grant from Kiniksa

[C. Michael Gibson MD @CMichaelGibson]

TWILIGHT-ACS slides presented at #AHA19 demonstrate that, in patients with NSTE-ACS undergoing PCI, continuing treatment with ticagrelor alone lowers risk of bleeding without increasing the risk of an ischemic event over one year.

Full slide deck: https://t.co/MAFWTyimFX

[C. Michael Gibson MD @CMichaelGibson]

DAPA-HF Substudy slides presented at #AHA19 demonstrate that Dapagliflozin could potentially be used to treat HFrEF in patients with and without diabetes.

Full slide deck: https://t.co/vo0sk6pJBZ

[C. Michael Gibson MD @CMichaelGibson]

ORION-10: Inclisiran, a twice-yearly siRNA injectable reduced LDL-cholesterol levels by 58% in pts with ASCVD and elevated LDL compared with placebo.

Full slides are posted here: https://t.co/qE0MuMWnDC

Sponsored by an independent educational grant from The Medicines Company

[C. Michael Gibson MD @CMichaelGibson]

EVAPORATE Trial slides presented at #AHA19 suggest Icosapent Ethyl in addition to statin therapy provides benefit on plaque characteristics.

Full slide deck: https://t.co/XpmyCxtn3h

[C. Michael Gibson MD @CMichaelGibson]

Patients w/ stable CAD & moderate-severe ischemia experiencing angina had early & sustained improvements in angina and QoL w/ an invasive strategy compared to OMT in the ISCHEMIA Quality of Life data presented at
#AHA19

Review the full slides here:
https://t.co/x6pQzxNLWF

[C. Michael Gibson MD @CMichaelGibson]

In pts with recent ischemic stroke or TIA & evidence of atherosclerotic disease, a target of <70 mg/dL LDL cholesterol had lower risk of subsequent CV events compared to pts w/ an LDL cholesterol target of 100+/-10 mg/dL #AHA19

View the full deck here: https://t.co/8UoF0b0c8h

[C. Michael Gibson MD @CMichaelGibson]

Dr. Uma Sinha Presents: Differential Transthyretin Binding, Kinetic Stability and Additive Ex Vivo Stabilization by AG10 Compared to Tafamidis

View the full poster here: https://t.co/rV1vEqOYUI

Sponsored by an unrestricted educational grant from Eidos Therapeutics

[C. Michael Gibson MD @CMichaelGibson]

ORION-9 slides presented at #AHA19 demonstrate a highly significant lowering of LDL-C relative to placebo with Inclisiran for patients with Heterozygous Familial Hypercholesterolemia.

Full deck here: https://t.co/X1RlMOFQuK

[C. Michael Gibson MD @CMichaelGibson]

The late-breaking science continues! COMPLETE: staged complete revasc superior to culprit only revasc in reducing CV death/MI/revasc in patients with STEMI and multivessel CAD #ESCCongress

[Andrew Chapman @chapdoc1]

In an RCT of 31,492 patients with suspected acute coronary syndrome, a rule out pathway using a hs-TnI risk stratification threshold of 5ng/L reduced length of stay by 3.3hrs (57% ⬆️ in ED discharge) with no evidence of harm at one year #ESCCongress #HiSTORIC #troponin

[Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 @DrMarthaGulati]

#women do worse after #STEMI even with less obstructive CAD as demonstrated in their @JAMA_current paper by @RBugiardini #ESCCongress

@lesleejshaw @SilCastelletti @mirvatalasnag @CMichaelGibson

[Robert W. Yeh @rwyeh]

More stunning results published in NEJM. ISAR REACT 5. Prasugrel vs ticagrelor for ACS:

Prasugrel reduces death/MI/stroke at 1 year. No difference in bleeding. Wow.

#ESCcongress2019

[Nadeen N. Faza, M.D. @NadeenFaza]

#ESCCongress Paragon-HF Trial 💊: angiotensin-neprilysin ❌ did not result in ⬇️ in HF hospitalization or CV death in patients with #HFpEF! @visualmedapp #CardioTwitter #ACCFIT @ACCinTouch #ACCWIC @HMHCardioFellow @HMethodistCV @DeBakeyCVedu

[Shelley Zieroth @ShelleyZieroth]

I was in the back outside! There was applause with this slide at #ESCCongress for the new addition of SGlT2i's in the management of HFrEF, even in non-diabetics!! @GiuseppeGalati_ @MihaiTrofenciuc @paomorejon @hvanspall

[C. Michael Gibson MD @CMichaelGibson]

Chairing session on high sensitivity troponins: state of the art slides from Christian Mueller including ESC 0/1 algorithm #ESCCongress